Development of a Humanized Anti-Fibrotic Antibody Targeting Extracellular Collagen Assembly to Reduce Post-Traumatic Scarring
Antibodies · 11.11.2026 · 15 (6) · 108
DOI: 10.3390/antib15060108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 11.11.2026. Verfasst von Andrew R. Mendelsohn und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Background
Excessive accumulation of fibrillar collagen causes pathological scarring and fibrosis. A promising anti-fibrotic strategy targets the extracellular assembly of collagen fibrils rather than intracellular synthesis pathways. We previously developed a chimeric monoclonal anti-collagen antibody (ACA) that targets the C-terminal telopeptide of the α2(I) chain (α2Ct) of human collagen I and effectively disrupts fibrillogenesis. This study details the engineering of a humanized antibody variant optimized for therapeutic application, augmented with a collagen-binding peptide (CBP) to enhance targeted retention in fibrotic tissues.
Methods
A humanized ACA was engineered using in silico homology modeling, complementarity-determining region grafting, and sequence optimization to eliminate chemical liabilities. Variants were expressed in mammalian cells and evaluated for binding kinetics and specificity. To improve spatial localization, the CBP was fused to the antibody. The lead variant was assessed for in vitro cytotoxicity and matrix retention. In addition, small-group pilot studies were performed in a rabbit model of post-traumatic knee arthrofibrosis to provide basic information on the efficacy of the selected antibody construct.
Results
The humanized ACA variants maintained high specificity and affinity for the α2Ct target. Fusing the CBP to the C-terminus of the light chain generated a construct (C-cbpACA) that enhanced matrix retention in cell culture conditions without compromising target engagement or causing cytotoxicity. In the rabbit arthrofibrosis model, intra-articular C-cbpACA delivery was associated with reduced flexion contracture and decreased total collagen deposition in the joint capsule relative to historical cohorts.
Conclusions
These findings characterize a humanized, matrix-targeted ACA variant and provide preliminary support for its further evaluation in post-traumatic arthrofibrosis, though this small pilot study does not establish definitive superiority in efficacy or safety.
Förderung
- National Institutes of Health
Zitieren
APA
Mendelsohn, A. R., Yu, B., Fertala, J., Larrick, J. W., & Fertala, A. (2026). Development of a Humanized Anti-Fibrotic Antibody Targeting Extracellular Collagen Assembly to Reduce Post-Traumatic Scarring. Antibodies, 15(6), 108. https://doi.org/10.3390/antib15060108
Vancouver
Mendelsohn AR, Yu B, Fertala J, Larrick JW, Fertala A. Development of a Humanized Anti-Fibrotic Antibody Targeting Extracellular Collagen Assembly to Reduce Post-Traumatic Scarring. Antibodies. 2026;15(6):108. doi:10.3390/antib15060108
BibTeX
@article{Mendelsohn2026,
author = {Mendelsohn, Andrew R. and Yu, Bo and Fertala, Jolanta and Larrick, James W. and Fertala, Andrzej},
title = {Development of a Humanized Anti-Fibrotic Antibody Targeting Extracellular Collagen Assembly to Reduce Post-Traumatic Scarring},
journal = {Antibodies},
year = {2026},
volume = {15},
number = {6},
pages = {108},
doi = {10.3390/antib15060108}
}
EUVIMED